CDTX - Cidara Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Performance Price Targets & Ratings Chart

CDTX is currently covered by 1 analysts with an average potential upside of $4.47 (173.88%) from yesterday's end of day stock price of $0.74. Cidara Therapeutics activity chart has currently 9 price targets and 15 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 19.44% with an average time for these price targets to be met of 27 days.

Highest price target for CDTX is $2, Lowest price target is $1, average price target is $1.5.

Most recent stock forecast was given by ED ARCE from HCWAINWRIGHT on 22-Sep-2023. First documented stock forecast 11-May-2015.

Currently, out of the existing stock ratings of CDTX - 3 which are a Buy (100%)

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

6

$5.06 (538.30%)

6

2 months 18 days ago

0/7 (0%)

$4.87 (432.82%)

Buy

5

$4.14 (481.40%)

5

4 months 9 days ago

0/2 (0%)

$3.68 (295.67%)

Buy

1 years 7 months 26 days ago

1/1 (100%)

$-2.15 (-14.19%)

158

Buy

8

1 years 7 months 26 days ago

0/3 (0%)

$6.41 (284.34%)

Buy

5

$4.06 (431.91%)

8

3 years 3 months 14 days ago

0/3 (0%)

$3.46 (106.54%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CDTX (Cidara Therapeutics) average time for price targets to be met?

On average it took 27 days on average for the stock forecasts to be realized with a an average price target met ratio 19.44

Which analyst has the current highest performing score on CDTX (Cidara Therapeutics) with a proven track record?

ROBERT DRISCOLL

Which analyst has the current lower performing score on CDTX (Cidara Therapeutics) with a proven track record?

KEVIN DEGEETER

Which analyst has the most public recommendations on CDTX (Cidara Therapeutics)?

Robert Driscoll works at WEDBUSH and has 10 price targets and 7 ratings on CDTX

Which analyst is the currently most bullish on CDTX (Cidara Therapeutics)?

Paul Matteis with highest potential upside - $15.06

Which analyst is the currently most reserved on CDTX (Cidara Therapeutics)?

David Nierengarten with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart